{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:00:37Z","timestamp":1793145637393,"version":"4.5.0"},"reference-count":20,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,2]]},"abstract":"<jats:p>Pentoxifylline is a tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitor that also attenuates the immune response and decreases tissue inflammation. The association of pentoxifylline with antimony improves the cure rate of mucosal and cutaneous leishmaniasis. In this randomized and double blind pilot trial, cure rate was higher, although not significant, in patients who received antimony plus pentoxifylline than in those patients receiving antimony plus placebo. A significant decrease in TNF-\u03b1 and interferon-\u03b3 (IFN-\u03b3) levels during therapy was more pronounced in the antimony plus pentoxifylline group, whereas CCL-3 (Chemokine [C-C motif] ligand 3) decreased similarly in both groups. The increased levels of CXCL-9 (Chemokine [C-X-C motif] ligand 9) during therapy were lower in the antimony plus pentoxifylline group. Therapy with pentoxifylline modifies cytokines and chemokines production, which may be associated with therapeutic outcome.<\/jats:p>","DOI":"10.4269\/ajtmh.12-0729","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T02:58:54Z","timestamp":1393297134000},"page":"617-620","source":"Crossref","is-referenced-by-count":40,"title":["Clinical and Immunological Outcome in Cutaneous Leishmaniasis Patients Treated with Pentoxifylline"],"prefix":"10.4269","volume":"90","author":[{"given":"Gra\u00e7a","family":"Brito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra","family":"Dourado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila","family":"Polari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Celestino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas P.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Queiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar M.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo R. L.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Passos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"R1","series-title":"Leishmaniasis. Tropical Diseases Research","author":"WHO","year":"1998"},{"key":"R2","series-title":"Am J Trop Med Hyg","first-page":"551","article-title":"Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis","volume":"84","author":"Newlove","year":"2011"},{"key":"R3","series-title":"PLoS Negl Trop Dis","first-page":"e912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial","volume":"4","author":"Machado","year":"2010"},{"key":"R4","series-title":"Rev Soc Bras Med Trop","first-page":"7","article-title":"Evaluation of IFN-gamma and TNF-alpha as immunological markers of clinical outcome in cutaneous leishmaniasis","volume":"35","author":"D'Oliveira","year":"2002"},{"key":"R5","series-title":"Immunol Lett","first-page":"226","article-title":"Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis","volume":"101","author":"Antonelli","year":"2005"},{"key":"R6","series-title":"J Biol Regul Homeost Agents","first-page":"91","article-title":"Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings","volume":"11","author":"Dinarello","year":"1997"},{"key":"R7","series-title":"Infect Immun","first-page":"837","article-title":"Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis","volume":"62","author":"Melby","year":"1994"},{"key":"R8","series-title":"J Infect Dis","first-page":"1793","article-title":"Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study","volume":"190","author":"Santos","year":"2004"},{"key":"R9","series-title":"Drugs","first-page":"50","article-title":"Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy","volume":"34","author":"Ward","year":"1987"},{"key":"R10","series-title":"Scand J Immunol","first-page":"461","article-title":"Effect of pentoxifylline on levels of pro-inflammatory cytokines during chronic hepatitis C","volume":"63","author":"Gutierrez-Reyes","year":"2006"},{"key":"R11","series-title":"Surgery","first-page":"192","article-title":"Pentoxifylline suppression of tumor necrosis factor gene transcription","volume":"110","author":"Doherty","year":"1991"},{"key":"R12","series-title":"Int J Dermatol","first-page":"819","article-title":"Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis","volume":"45","author":"Sadeghian","year":"2006"},{"key":"R13","series-title":"Clin Infect Dis","first-page":"788","article-title":"Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis","volume":"44","author":"Machado","year":"2007"},{"key":"R14","series-title":"Am J Trop Med Hyg","first-page":"87","article-title":"Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony","volume":"65","author":"Lessa","year":"2001"},{"key":"R15","series-title":"Am J Trop Med Hyg","first-page":"79","article-title":"Selection of a skin test antigen for American visceral leishmaniasis","volume":"35","author":"Reed","year":"1986"},{"key":"R16","series-title":"J Exp Med","first-page":"155","article-title":"Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo","volume":"182","author":"Angiolillo","year":"1995"},{"key":"R17","series-title":"Cell Immunol","first-page":"131","article-title":"Interaction of monocytes with vascular endothelial cells synergistically induces interferon gamma-inducible protein 10 expression through activation of specific cell surface molecules and cytokines","volume":"219","author":"Kasama","year":"2002"},{"key":"R18","series-title":"Parasite Immunol","first-page":"295","article-title":"Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis","volume":"24","author":"Ritter","year":"2002"},{"key":"R19","series-title":"Blood","first-page":"e74","article-title":"Nomenclature of monocytes and dendritic cells in blood","volume":"116","author":"Ziegler-Heitbrock","year":"2010"},{"key":"R20","series-title":"Blood","first-page":"e50","article-title":"SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset","volume":"118","author":"Zawada","year":"2011"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/90\/4\/article-p617.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/90\/4\/article-p617.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/90\/4\/article-p617.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T21:29:47Z","timestamp":1723066187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/90\/4\/article-p617.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,2]]},"references-count":20,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.12-0729","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,2]]}}}